Study summary

A blood-vessel-blocking pill slowed but did not shrink adenoid cystic carcinoma

Regorafenib in adenoid cystic carcinoma · 38 people, phase 2 · Published December 2024, Clinical Cancer Research

45%progression-free at 6 months

What was tested

Regorafenib, a multi-target kinase inhibitor pill, for recurrent or metastatic adenoid cystic carcinoma.

What they found

What it means

Shows why adenoid cystic carcinoma needs new approaches; NOTCH and immune-based strategies are being explored.

Clin Cancer Res, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.